Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
Recruiting · Phase 2 · NCT06555133
Conditions: Colorectal Carcinoma Metastatic in the Liver
At a glance
- Research payments reported, 2025
- $27,039
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Brown University (with Sirtex Medical, Genentech, Inc.)
- Tested
- yttrium-90 radioembolization (combination_product)
- Dates
- Started 2025-04-07; completion 2029-09-01
- Results posted
- Not yet
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
From ClinicalTrials.gov, last updated 2026-08-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sirtex Medical Inc reported $27,039 in research payments for this study in 2025 (2 payments).
Products named: Sir-Spheres Microspheres
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.